海王生物(000078) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥7,375,593,948.22, representing a decrease of 8.81% compared to ¥8,087,937,989.71 in the same period last year[5] - Net profit attributable to shareholders was ¥23,715,783.03, down 44.38% from ¥42,641,426.53 year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥74,743,595.07, a decline of 257.78% compared to ¥47,372,296.28 in the previous year[5] - Basic and diluted earnings per share were both ¥0.0090, down 44.44% from ¥0.0162 year-on-year[5] - Total operating revenue for the current period is ¥7,375,593,948.22, a decrease of 8.8% from ¥8,087,937,989.71 in the previous period[17] - Net profit for the current period is ¥52,955,598.60, down 23.5% from ¥69,171,556.13 in the previous period[18] - Total comprehensive income for the period was CNY 52,955,598.60, a decrease from CNY 69,171,556.13 in the previous period[19] - Net income attributable to the parent company was CNY 23,715,783.03, down from CNY 42,641,426.53 year-over-year[19] Cash Flow and Assets - The company's cash flow from operating activities was ¥47,431,311.19, a decrease of 16.43% from ¥56,755,485.31 in the same period last year[5] - Cash inflows from operating activities totaled CNY 8,409,891,136.83, a decline from CNY 9,411,431,958.97[19] - Cash outflows from operating activities were CNY 8,362,459,825.64, compared to CNY 9,354,676,473.66 in the previous period[19] - Net cash flow from operating activities was CNY 47,431,311.19, down from CNY 56,755,485.31[19] - Cash and cash equivalents decreased to CNY 3,275,636,071.84 from CNY 3,456,273,633.71[14] - The ending balance of cash and cash equivalents was CNY 984,880,498.93, down from CNY 1,102,450,212.12[20] - The company reported a total current assets of CNY 25,757,120,262.87, a slight decrease from CNY 25,834,823,219.04 at the beginning of the period[14] - The company's total assets amount to ¥28,603,975,902.91, slightly down from ¥28,798,320,164.17[16] - Total liabilities decreased to ¥25,674,501,567.09 from ¥25,954,556,650.61, a reduction of 1.1%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 126,898[10] - The controlling shareholder changed to Silk Spun Group, which now holds 12% of the company's shares[12] - The company has a total of 1,216,445,128 shares held by Shenzhen Haiwang Group, the largest shareholder[11] Strategic Initiatives - The company plans to issue up to 620,000,000 shares to specific investors, pending regulatory approval[13] - The company signed a cooperation agreement with Silk Spun Group, indicating potential strategic partnerships[12] - The company plans to focus on market expansion and new product development in the upcoming quarters[18] Non-Recurring Items and Investments - Non-recurring gains and losses totaled ¥98,459,378.10, primarily from the disposal of subsidiaries[6] - Investment income increased by 1290.07% year-on-year, mainly due to gains from the disposal of subsidiaries[8] - The company's long-term equity investments remained stable at CNY 193,571,404.87[14] - The company reported an investment income of ¥95,295,953.60, compared to a loss of ¥8,007,570.45 in the previous period[17] Operating Costs and Expenses - Total operating costs decreased to ¥7,352,946,262.98 from ¥7,981,269,889.39, reflecting a reduction of 7.8%[17] - Research and development expenses increased to ¥11,250,327.04 from ¥10,122,756.35, indicating a rise of 11.2%[17] Audit and Compliance - The first quarter report was not audited[21] - The company is committed to timely information disclosure regarding major events as per regulatory requirements[13]